

You are invited to attend an evening virtual presentation on:

Understanding the Impact of Unplanned Psychotropic Medication Switches on Patient Outcomes

EXPERT: JEFFERY HABERT, MD

MODERATOR: PENNY TSANG, PHARMACIST

DATE: MONDAY, APRIL 26TH 2021

TIME: 7:00 PM PRESENTATION

OBJECTIVES:

UNDERSTAND THE REGULATORY REQUIREMENTS FOR APPROVAL OF INNOVATOR MEDICINES AND GENERICS IN CANADA

EXPLORE POTENTIAL AREAS OF CONCERN WITH THE GENERAL USE OF GENERIC PSYCHOTROPIC MEDICATIONS

DEMONSTRATE THE CONSEQUENCES OF SWITCHES WHEN IT COMES TO PSYCHOTROPIC MEDICATION

The link to join the webinar will be emailed to HCPs who RSVP

Pfizer Canada takes seriously the presence of the novel coronavirus (COVID-19) in Canada and its potential effect on Canadians. We are pleased to offer this learning activity to you virtually so that you may play your part in avoiding community spread of COVID-19. We require you to participate in this virtual learning event individually, thereby minimizing group gatherings and close contact with others.

Please RSVP (with your name and email) to:

Christina Thibeault before Sunday, April 25th 2021

Email: christina.thibeault@pfizer.com or Mobile(Text/ call): 416-834-8885

Please note that a minimum number of attendees is required for this learning event to take place. Under the guidance of the Innovative Medicines Canada Code of Conduct, this event is for healthcare professionals only. This learning program was supported by a grant from Pfizer Canada

